Compound Evidence File
#EC-2026-0055
MOTS-C
Filed under Peptides. The bureau holds 184 laboratory returns for this compound from 82 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
82 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 4 | 10.0 | 9.9 | 10.0 | 21 May 2026 | 21 May 2026 |
| Paradigm PeptideCASE #VI-2026-0759 | X | 1 | 10.0 | 10.0 | 10.0 | 14 Jan 2025 | 14 Jan 2025 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 6 | 9.9 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| PeptiAtlasCASE #VI-2026-0739 | X | 1 | 9.8 | 9.8 | 9.8 | 11 Jun 2025 | 11 Jun 2025 |
| Trusted PeptideCASE #VI-2026-0499 | X | 1 | 9.4 | 9.4 | 9.4 | 25 Apr 2025 | 25 Apr 2025 |
| LipeptidesCASE #VI-2026-0863 | X | 1 | 9.1 | 9.1 | 9.1 | 17 Dec 2024 | 17 Dec 2024 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 2 | 8.9 | 8.2 | 9.6 | 24 May 2026 | 24 May 2026 |
| Bulk Peptide SupplyCASE #VI-2026-0446 | X | 2 | 8.9 | 8.1 | 9.7 | 3 Jun 2025 | 25 May 2026 |
| Laicuinuo LCNCASE #VI-2026-0223 | X | 1 | 8.9 | 8.9 | 8.9 | 27 Feb 2025 | 27 Feb 2025 |
| Amplified AminoCASE #VI-2026-0748 | X | 1 | 8.8 | 8.8 | 8.8 | 25 Apr 2025 | 25 Apr 2025 |
| Atomik LabzCASE #VI-2026-0327 | X | 4 | 8.7 | 7.9 | 9.9 | 16 Mar 2025 | 26 Jan 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 8 | 8.5 | 7.3 | 9.5 | 24 May 2026 | 24 May 2026 |
| Zen PeptidesCASE #VI-2026-0940 | X | 1 | 8.5 | 8.5 | 8.5 | 20 Jun 2025 | 20 Jun 2025 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 3 | 8.4 | 7.6 | 9.3 | 24 May 2026 | 24 May 2026 |
| Xingruida XDRCASE #VI-2026-0898 | X | 3 | 8.3 | 7.6 | 8.7 | 7 May 2025 | 23 May 2026 |
| Shandong Shengyuan Peptide TechnologyCASE #VI-2026-0634 | X | 2 | 8.3 | 8.2 | 8.4 | 9 Jun 2025 | 26 Jan 2026 |
| Reta-PeptideCASE #VI-2026-0756 | X | 5 | 8.2 | 6.2 | 10.0 | 14 Jan 2025 | 20 May 2026 |
| HkRoidsCASE #VI-2026-0784 | X | 1 | 8.0 | 8.0 | 8.0 | 28 Mar 2025 | 28 Mar 2025 |
| Shanghai BaojuCASE #VI-2026-0233 | X | 1 | 8.0 | 8.0 | 8.0 | 14 Jan 2025 | 14 Jan 2025 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 8 | 7.9 | 6.6 | 9.2 | 23 May 2026 | 23 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 4 | 7.8 | 6.0 | 8.8 | 23 May 2026 | 23 May 2026 |
| Qing Li PeptideCASE #VI-2026-0469 | X | 3 | 7.7 | 7.2 | 8.1 | 2 Apr 2025 | 24 May 2026 |
| Skye PeptidesCASE #VI-2026-0451 | X | 3 | 7.7 | 6.2 | 10.0 | 6 May 2025 | 21 May 2026 |
| Qingdao Saber Technology Pharma QSTCASE #VI-2026-0467 | X | 1 | 7.6 | 7.6 | 7.6 | 2 Apr 2025 | 2 Apr 2025 |
| Verified PeptidesCASE #VI-2026-0407 | X | 2 | 7.5 | 6.6 | 8.4 | 2 Jul 2025 | 23 May 2026 |
| Shanxi Qianyecao Biotech QYCCASE #VI-2026-0189 | X | 6 | 7.4 | 6.0 | 8.5 | 27 Feb 2025 | 24 May 2026 |
| HK PeptidesCASE #VI-2026-0140 | X | 11 | 7.3 | 5.8 | 9.0 | 2 Apr 2025 | 19 Jan 2026 |
| Xingtai Jiachuang TechnologyCASE #VI-2026-0712 | X | 1 | 7.3 | 7.3 | 7.3 | 20 Jun 2025 | 20 Jun 2025 |
| Polaris PeptidesCASE #VI-2026-0839 | X | 5 | 7.1 | 5.1 | 9.4 | 24 Apr 2025 | 24 May 2026 |
| NextGen HealthCASE #VI-2026-0604 | X | 1 | 7.1 | 7.1 | 7.1 | 17 Dec 2024 | 17 Dec 2024 |
| EHZ PeptidesCASE #VI-2026-0296 | C | 2 | 7.0 | 5.7 | 8.3 | 20 Jun 2025 | 24 May 2026 |
| Golden EagleCASE #VI-2026-0680 | X | 1 | 7.0 | 7.0 | 7.0 | 8 Jul 2025 | 8 Jul 2025 |
| Planet PeptideCASE #VI-2026-0092 | X | 4 | 6.9 | 5.5 | 7.9 | 8 Jul 2025 | 20 May 2026 |
| Eternal PeptidesCASE #VI-2026-0842 | X | 2 | 6.8 | 6.2 | 7.4 | 27 Feb 2025 | 19 Jan 2026 |
| ScienceCASE #VI-2026-0636 | X | 1 | 6.8 | 6.8 | 6.8 | 16 Mar 2025 | 16 Mar 2025 |
| NexaphCASE #VI-2026-0944 | X | 7 | 6.7 | 4.3 | 8.9 | 13 Feb 2025 | 26 Jan 2026 |
| Pure Tested PeptidesCASE #VI-2026-0225 | X | 1 | 6.7 | 6.7 | 6.7 | 11 Jun 2025 | 11 Jun 2025 |
| Peptide-SCASE #VI-2026-0111 | X | 7 | 6.6 | 3.6 | 9.8 | 27 Feb 2025 | 24 May 2026 |
| Zhejiang Yichenkang BiotechnologyCASE #VI-2026-0269 | X | 4 | 6.6 | 4.8 | 9.5 | 2 Jul 2025 | 20 May 2026 |
| Alpha-GenCASE #VI-2026-0905 | X | 2 | 6.5 | 6.4 | 6.5 | 20 Jun 2025 | 19 Jan 2026 |
| Shanghai OuDaXin New Material Technology CenterCASE #VI-2026-0498 | E | 3 | 6.4 | 4.8 | 8.7 | 24 Apr 2025 | 21 May 2026 |
| Shandong Nuoweiou Medical Technology CoCASE #VI-2026-0076 | X | 1 | 6.4 | 6.4 | 6.4 | 8 Jul 2025 | 8 Jul 2025 |
| Eros PeptidesCASE #VI-2026-0918 | X | 1 | 6.3 | 6.3 | 6.3 | 13 Feb 2025 | 13 Feb 2025 |
| PeptiLab ResearchCASE #VI-2026-0267 | X | 1 | 6.2 | 6.2 | 6.2 | 20 Jun 2025 | 20 Jun 2025 |
| Guangzhou Lengiuanhuang CosmeticsCASE #VI-2026-0228 | X | 1 | 6.2 | 6.2 | 6.2 | 16 Mar 2025 | 16 Mar 2025 |
| LN PeptidesCASE #VI-2026-0781 | X | 1 | 6.1 | 6.1 | 6.1 | 11 Jun 2025 | 11 Jun 2025 |
| SRY LabsCASE #VI-2026-0657 | X | 9 | 6.0 | 3.6 | 8.3 | 13 Feb 2025 | 21 May 2026 |
| Regenerative ResearchCASE #VI-2026-0349 | X | 1 | 6.0 | 6.0 | 6.0 | 13 Feb 2025 | 13 Feb 2025 |
| Zztai PeptideCASE #VI-2026-0192 | X | 1 | 6.0 | 6.0 | 6.0 | 25 Apr 2025 | 25 Apr 2025 |
| Bio PepzCASE #VI-2026-0436 | X | 1 | 5.9 | 5.9 | 5.9 | 14 Jan 2025 | 14 Jan 2025 |
| HealthTide BiotechCASE #VI-2026-0955 | X | 1 | 5.9 | 5.9 | 5.9 | 9 Jun 2025 | 9 Jun 2025 |
| Dragon PharmaCASE #VI-2026-0519 | X | 1 | 5.9 | 5.9 | 5.9 | 27 Feb 2025 | 27 Feb 2025 |
| Peptronix Bio PTBCASE #VI-2026-0979 | X | 1 | 5.8 | 5.8 | 5.8 | 14 Jan 2025 | 14 Jan 2025 |
| Amino AsylumCASE #VI-2026-0828 | X | 1 | 5.8 | 5.8 | 5.8 | 7 May 2025 | 7 May 2025 |
| TSC Top Supplements ChinaCASE #VI-2026-0523 | X | 7 | 5.7 | 2.6 | 8.5 | 8 Jul 2025 | 20 May 2026 |
| Haikou Mingheng BiotechnologyCASE #VI-2026-0126 | X | 1 | 5.7 | 5.7 | 5.7 | 8 Jul 2025 | 8 Jul 2025 |
| Haikou Mingheng TechnologyCASE #VI-2026-0250 | X | 1 | 5.5 | 5.5 | 5.5 | 24 Apr 2025 | 24 Apr 2025 |
| Pure RawzCASE #VI-2026-0767 | X | 1 | 5.4 | 5.4 | 5.4 | 13 Feb 2025 | 13 Feb 2025 |
| Forever Young PharmacyCASE #VI-2026-0654 | X | 2 | 5.3 | 4.0 | 6.7 | 25 Apr 2025 | 23 May 2026 |
| InjectifyCASE #VI-2026-0387 | X | 1 | 5.3 | 5.3 | 5.3 | 3 Jul 2025 | 3 Jul 2025 |
| Chimera PeptidesCASE #VI-2026-0260 | X | 1 | 5.3 | 5.3 | 5.3 | 2 Apr 2025 | 2 Apr 2025 |
| BeiBangAnCASE #VI-2026-0899 | X | 2 | 5.2 | 5.2 | 5.3 | 24 Apr 2025 | 17 May 2026 |
| Loti LabsCASE #VI-2026-0171 | X | 1 | 5.2 | 5.2 | 5.2 | 21 May 2025 | 21 May 2025 |
| CellupepCASE #VI-2026-0888 | X | 1 | 5.2 | 5.2 | 5.2 | 2 Jul 2025 | 2 Jul 2025 |
| Glamgurcraft Innovations Foreign TradeCASE #VI-2026-0348 | X | 1 | 5.2 | 5.2 | 5.2 | 2 Jul 2025 | 2 Jul 2025 |
| Top PeptideCASE #VI-2026-0721 | X | 2 | 5.0 | 3.5 | 6.5 | 27 Feb 2025 | 19 Jan 2026 |
| Xian Yihang TechnologyCASE #VI-2026-0656 | X | 1 | 5.0 | 5.0 | 5.0 | 25 Apr 2025 | 25 Apr 2025 |
| Shanghai ERP peptide BiotechnologyCASE #VI-2026-0500 | X | 1 | 5.0 | 5.0 | 5.0 | 3 Jun 2025 | 3 Jun 2025 |
| Hunan Ruiwang Technology CenterCASE #VI-2026-0027 | X | 1 | 4.9 | 4.9 | 4.9 | 27 Feb 2025 | 27 Feb 2025 |
| Wolverine PeptidesCASE #VI-2026-0262 | X | 1 | 4.8 | 4.8 | 4.8 | 28 Mar 2025 | 28 Mar 2025 |
| Alimo PeptideCASE #VI-2026-0524 | X | 1 | 4.7 | 4.7 | 4.7 | 6 May 2025 | 6 May 2025 |
| Nanjing Xiyuxun Technology XYXCASE #VI-2026-0433 | X | 1 | 4.6 | 4.6 | 4.6 | 21 May 2025 | 21 May 2025 |
| Qingdao VitaConin International TradingCASE #VI-2026-0504 | X | 1 | 4.1 | 4.1 | 4.1 | 16 Mar 2025 | 16 Mar 2025 |
| Swiss ChemsCASE #VI-2026-0030 | X | 1 | 3.8 | 3.8 | 3.8 | 13 Feb 2025 | 13 Feb 2025 |
| Peptide GurusCASE #VI-2026-0854 | X | 2 | 3.0 | 2.1 | 3.9 | 6 May 2025 | 20 May 2026 |
| WllyBIOCASE #VI-2026-0470 | X | 1 | 3.0 | 3.0 | 3.0 | 21 May 2025 | 21 May 2025 |
| HK Fat CatCASE #VI-2026-0376 | X | 1 | 2.5 | 2.5 | 2.5 | 6 May 2025 | 6 May 2025 |
| Richards Biotech Simply RichardsCASE #VI-2026-0307 | X | 1 | 1.9 | 1.9 | 1.9 | 21 May 2025 | 21 May 2025 |
| PepKitsCASE #VI-2026-0320 | X | 1 | 0.4 | 0.4 | 0.4 | 24 Apr 2025 | 24 Apr 2025 |
| Hebei Chengtong TechnologyCASE #VI-2026-0520 | X | 1 | 0.1 | 0.1 | 0.1 | 2 Jul 2025 | 2 Jul 2025 |
| Weifang Xingbei International TradeCASE #VI-2026-0766 | X | 1 | 0.0 | 0.0 | 0.0 | 16 Mar 2025 | 16 Mar 2025 |
| Peptide ArkCASE #VI-2026-0350 | X | 1 | 0.0 | 0.0 | 0.0 | 25 Apr 2025 | 25 Apr 2025 |
Open any subject to view the batch-level evidence for MOTS-C alone.